Role of MB Isoforms (Isomers) in the Early Diagnosis of Acute Myocardial Infarction.

Abstract

In addition to electrocardiogram (ECG), analysis of creatinine phosphokinase (CPK), lactate dehydrogenase (LDH) and their isoenzymes is commonlyemployed to diagnose acute myocardial infarction (AMI). The aim of this study was to observe the efficiency of isomers of CPKfor early diagnosis of AMI. ECG, though useful in many ways, is not 100% sensitive. The drawback involved with CPK and LDH isoenzymes is the time lag factor in diagnosing AMI early enough for interventional therapy. Recently the subunits of these isoenzymes, namely MMand now the MB isomers are being tested for their effectiveness in the early diagnosis ofAMI. In our experience MB isomers were found to be accurate markers in the early diagnosis of AMI. They were especially valuable in diagnosing myocardial infarction not detectable by ECGin cases such as non-Q AMI, cardiomyopathy, and bundle branch block among other such cases. (Internal Medicine 33: 210-215, 1994)

Open-label clinical trial of bezafibrate treatment in patients with fatty acid oxidation disorders in Japan

“…Therefore, the frequency of myopathic attacks observed during the observation and administration periods was lower than that before initiation of this study. Moreover, such episodes might also be influenced by a time lag in the elevation of serum CK levels [ 24 ]. The elevation of CK might be delayed following the manifestation of patient symptoms such as myalgia and fatigue.…”

Creatinine kinase isoenzyme–MB: A simple prognostic biomarker in patients with pulmonary embolism treated with thrombolytic therapy

“…Creatinine kinase isoenzyme MB (CK-MB) is an important biomarker for detecting myocardial injury [13]. The relationship between admission CK-MB levels and in-hospital and long-term unfavourable clinical outcomes in patients with PE who were treated with tissue-plasminogen activator (t-PA) has not yet been investigated.…”